Neurology Journal

•  
• Overview
•  
• Identity
•  
• View All
•  

Overview

publication venue for

• Association of Self-Reported Sleep Characteristics With Neuroimaging Markers of Brain Aging Years Later in Middle-Aged Adults..  103:-. 2024
• Life's Essential 8 and Poor Brain Health Outcomes in Middle-Aged Adults..  103:-. 2024
• Association of Seizure Control With Cognition in People With Normal Cognition and Mild Cognitive Impairment..  103:-. 2024
• Association of Changes in C-Reactive Protein Level Trajectories Through Early Adulthood With Cognitive Function at Midlife: The CARDIA Study..  103:-. 2024
• The Parkinson's Disease Composite of Executive Functioning: A Measure for Detecting Cognitive Decline in Clinical Trials..  103:-. 2024
• Long-Term Depressive Symptom Trajectories and Midlife Cognition: The CARDIA Study..  103:-. 2024
• Associations Between Self and Study Partner Report of Cognitive Decline With Regional Tau in a Multicohort Study..  102:-. 2024
• Predicting Driving Cessation Among Cognitively Normal Older Drivers: The Role of Alzheimer Disease Biomarkers and Clinical Assessments..  102:-. 2024
• Investigating White Matter Neuroinflammation in Alzheimer Disease Using Diffusion-Based Neuroinflammation Imaging..  102:-. 2024
• Associations of Polycystic Ovary Syndrome With Indicators of Brain Health at Midlife in the CARDIA Cohort..  102:-. 2024
• Screening for Cognitive Decline in Isolated/Idiopathic REM Sleep Behavior Disorder: Which Test Is Best?.  102:-. 2024
• Validation of the RBD Symptom Severity Scale in the North American Prodromal Synucleinopathy Consortium..  102:-. 2024
• Association Between Sleep Quantity and Quality in Early Adulthood With Cognitive Function in Midlife..  102:-. 2024
• Association of Poor Oral Health With Neuroimaging Markers of White Matter Injury in Middle-Aged Participants in the UK Biobank..  102:-. 2023
• Emerging Subspecialties in Neurology: Women's Neurology..  102:-. 2023
• Association Between Triglycerides and Risk of Dementia in Community-Dwelling Older Adults: A Prospective Cohort Study..  101:e2288-e2299. 2023
• Clinical Reasoning: A 22-Year-Old Man With Multifocal Brain and Osseous Lesions..  101:1025-1031. 2023
• Association of Pathologic and Volumetric Biomarker Changes With Cognitive Decline in Clinically Normal Adults..  101:e2533-e2544. 2023
• Frequency of Orthostatic Hypotension in Isolated REM Sleep Behavior Disorder..  101:e2545-e2559. 2023
• Associations Between Traumatic Brain Injury and Cognitive Decline Among Older Male Veterans: A Twin Study..  101:e1761-e1770. 2023
• Clinical Reasoning: A 48-Year-Old Man With Spasticity and Progressive Ataxia..  101:e1747-e1752. 2023
• Association of Plasma Biomarkers of Alzheimer Disease With Cognition and Medical Comorbidities in a Biracial Cohort..  101:e1402-e1411. 2023
• Retrospective Evaluation of Neuropathologic Proxies of the Minimal Atrophy Subtype Compared With Corticolimbic Alzheimer Disease Subtypes..  101:e1412-e1423. 2023
• Polygenic Susceptibility to Hypertension and Cognitive Performance in Middle-aged Persons Without Stroke or Dementia..  101:e512-e521. 2023
• Clinicoradiologic and Neuropathologic Evaluation of Corticobasal Syndrome..  101:e289-e299. 2023
• Longitudinal Relationships of White Matter Hyperintensities and Alzheimer Disease Biomarkers Across the Adult Life Span..  101:e164-e177. 2023
• Associations of Enlarged Perivascular Spaces With Brain Lesions, Brain Age, and Clinical Outcomes in Chronic Traumatic Brain Injury..  101:e63-e73. 2023
• Genetic Moderation of the Association of β-Amyloid With Cognition and MRI Brain Structure in Alzheimer Disease..  101:e20-e29. 2023
• Association of Mitochondrial DNA Copy Number With Brain MRI Markers and Cognitive Function: A Meta-analysis of Community-Based Cohorts..  100:e1930-e1943. 2023
• Evaluating the Association Between Genetically Proxied Neurodevelopmental Language Phenotypes and the Risk of Primary Progressive Aphasia..  100:e1922-e1929. 2023
• Blood Biomarkers in Neurodegenerative Diseases: Implications for the Clinical Neurologist..  101:172-180. 2023
• Premature Cardiovascular Disease and Brain Health in Midlife: The CARDIA Study..  100:e1454-e1463. 2023
• Polygenic Susceptibility to Hypertension and Blood Pressure Control in Stroke Survivors..  100:e1587-e1597. 2023
• Interim Safety Profile From the Feasibility Study of the BrainGate Neural Interface System..  100:e1177-e1192. 2023
• Cognitive and Functional Trajectories in Older Adults With Prediagnostic Parkinson Disease..  100:e1386-e1394. 2022
• Association of Choroid Plexus Inflammation on MRI With Clinical Disability Progression Over 5 Years in Patients With Multiple Sclerosis..  100:e911-e920. 2022
• Combined Effects of Synaptic and Axonal Integrity on Longitudinal Gray Matter Atrophy in Cognitively Unimpaired Adults..  99:e2285-93. 2022
• Association of Obesity With Cognitive Decline in Black and White Americans..  100:e220-e231. 2022
• Estimating Bidirectional Transitions and Identifying Predictors of Mild Cognitive Impairment..  100:e297-e307. 2022
• Association of CSF GAP-43 With the Rate of Cognitive Decline and Progression to Dementia in Amyloid-Positive Individuals..  100:e275-e285. 2022
• Migraine, Migraine Disability, Trauma, and Discrimination in Sexual and Gender Minority Individuals..  99:e1549-e1559. 2022
• Opinion and Special Article: The Need for Specialized Training in Women's Neurology..  100:38-42. 2022
• Socioeconomic Status, Biological Aging, and Memory in a Diverse National Sample of Older US Men and Women..  99:e2114-e2124. 2022
• Association of β-Amyloid and Vascular Risk on Longitudinal Patterns of Brain Atrophy..  99:e270-80. 2022
• Investigating Heterogeneity and Neuroanatomic Correlates of Longitudinal Clinical Decline in Atypical Alzheimer Disease..  98:e2436-45. 2022
• Plasma P-tau181 and P-tau217 in Patients With Traumatic Encephalopathy Syndrome With and Without Evidence of Alzheimer Disease Pathology..  99:e594-e604. 2022
• Predicting Amyloid Positivity in Cognitively Unimpaired Older Adults: A Machine Learning Approach Using A4 Data..  98:e2425-e2435. 2022
• Effect of Race on Prediction of Brain Amyloidosis by Plasma Aβ42/Aβ40, Phosphorylated Tau, and Neurofilament Light..  99:e245-e257. 2022
• Prediction of Naming Outcome With FMRI Language Lateralization in Left Temporal Epilepsy Surgery..  98:e2337-e2346. 2022
• Clinical Trajectories at the End of Life in Autopsy-Confirmed Dementia Patients With Alzheimer Disease and Lewy Bodies Pathologies..  98:e2140-e2149. 2022
• Progression to Dementia or Reversion to Normal Cognition in Mild Cognitive Impairment as a Function of Late-Onset Neuropsychiatric Symptoms..  98:e2132-e2139. 2022
• Association of Emerging β-Amyloid and Tau Pathology With Early Cognitive Changes in Clinically Normal Older Adults..  98:e1512-e1524. 2022
• Clinicopathologic Factors Associated With Reversion to Normal Cognition in Patients With Mild Cognitive Impairment..  98:e2036-e2045. 2022
• Associations of Lower Extremity Peripheral Nerve Impairment and Risk of Dementia in Black and White Older Adults..  98:e1837-e1845. 2022
• Cerebral Microbleeds, Cerebral Amyloid Angiopathy, and Their Relationships to Quantitative Markers of Neurodegeneration..  98:e1605-e1616. 2022
• Associations of Stages of Objective Memory Impairment With Amyloid PET and Structural MRI: The A4 Study..  98:e1327-e1336. 2022
• Cognitive Outcome 1 Year After Mild Traumatic Brain Injury: Results From the TRACK-TBI Study..  98:e1248-e1261. 2022
• Association of Loneliness With 10-Year Dementia Risk and Early Markers of Vulnerability for Neurocognitive Decline..  98:e1337-e1348. 2022
• Twenty-Five-Year Change in Cardiac Structure and Function and Midlife Cognition: The CARDIA Study..  98:e1040-e1049. 2022
• Adherence to Antiseizure vs Other Medications Among US Medicare Beneficiaries With and Without Epilepsy..  98:e427-36. 2022
• Teaching NeuroImage: Neurovascular Consequences of Autonomic Dysreflexia..  98:e441-e442. 2022
• Association of Cognitive Impairment With Free Water in the Nucleus Basalis of Meynert and Locus Coeruleus to Transentorhinal Cortex Tract..  98:e700-e710. 2021
• Simulation-Based Assessment of Graduate Neurology Trainees' Performance Managing Acute Ischemic Stroke..  97:e2414-e2422. 2021
• Cerebral Amyloid Angiopathy Pathology and Its Association With Amyloid-β PET Signal..  97:e1799-e1808. 2021
• Predicting Symptom Onset in Sporadic Alzheimer Disease With Amyloid PET..  97:e1823-e1834. 2021
• Association of Age With Contrast-Enhancing Lesions Across the Multiple Sclerosis Disease Spectrum..  97:e1334-e1342. 2021
• Aducanumab, Amyloid Lowering, and Slowing of Alzheimer Disease..  97:543-544. 2021
• Comparing PET and MRI Biomarkers Predicting Cognitive Decline in Preclinical Alzheimer Disease..  96:e2933-43. 2021
• Experience of Community Neurologists Providing Care for Patients With Neurodegenerative Illness During the COVID-19 Pandemic..  97:e988-e995. 2021
• Clinical, Imaging, and Pathologic Characteristics of Patients With Right vs Left Hemisphere-Predominant Logopenic Progressive Aphasia..  97:e523-e534. 2021
• Progressive Neurologic Symptoms in the Setting of HIV: A Rare Case of Neurosymptomatic CSF HIV Escape..  97:389-390. 2021
• Association of Aortic Stiffness With Biomarkers of Neuroinflammation, Synaptic Dysfunction, and Neurodegeneration..  97:e329-e340. 2021
• Temporal Correlation of CSF and Neuroimaging in the Amyloid-Tau-Neurodegeneration Model of Alzheimer Disease..  97:e76-e87. 2021
• Visit-to-Visit Blood Pressure Variability, Neuropathology, and Cognitive Decline..  96:e2812-e2823. 2021
• Prospective Quantification of CSF Biomarkers in Antibody-Mediated Encephalitis..  96:e2546-e2557. 2021
• APOE.  96:e2414-e2428. 2021
• Association of Refractory Pain in the Acute Phase After Subarachnoid Hemorrhage With Continued Outpatient Opioid Use..  96:e2355-e2362. 2021
• Cardiovascular Risk Factors Across the Life Course and Cognitive Decline: A Pooled Cohort Study..  96:e2212-e2219. 2021
• APOE.  96:e2272-e2283. 2021
• National Institute of Neurological Disorders and Stroke Consensus Diagnostic Criteria for Traumatic Encephalopathy Syndrome..  96:848-863. 2021
• Traumatic Brain Injury and Incidence Risk of Sleep Disorders in Nearly 200,000 US Veterans..  96:e1792-e1799. 2021
• Association of Digital Clock Drawing With PET Amyloid and Tau Pathology in Normal Older Adults..  96:e1844-e1854. 2021
• Amyloid PET Imaging in Self-Identified Non-Hispanic Black Participants of the Anti-Amyloid in Asymptomatic Alzheimer's Disease (A4) Study..  96:e1491-e1500. 2021
• Child Neurology: Intractable Epilepsy and Transient Deficits in a Patient With a History of Herpes Simplex Virus Encephalitis..  96:679-681. 2021
• Memory Resilience in Alzheimer Disease With Primary Progressive Aphasia..  96:e916-e925. 2021
• Association of CSF Biomarkers With Hippocampal-Dependent Memory in Preclinical Alzheimer Disease..  96:e1470-e1481. 2021
• Association of Neighborhood Context, Cognitive Decline, and Cortical Change in an Unimpaired Cohort..  96:e2500-e2512. 2021
• APOE4.  96:e650-e661. 2020
• Defining the Lowest Threshold for Amyloid-PET to Predict Future Cognitive Decline and Amyloid Accumulation..  96:e619-e631. 2020
• Comparison of Clinical Outcomes 1 and 5 Years Post-Injury Following Combat Concussion..  96:e387-e398. 2020
• Association of Angiotensin II-Stimulating Antihypertensive Use and Dementia Risk: Post Hoc Analysis of the PreDIVA Trial..  96:e67-e80. 2020
• Apathy and risk of probable incident dementia among community-dwelling older adults..  95:e3280-e3287. 2020
• Effect of escitalopram dose and treatment duration on CSF Aβ levels in healthy older adults: A controlled clinical trial..  95:e2658-e2665. 2020
• Effect of escitalopram on Aβ levels and plaque load in an Alzheimer mouse model..  95:e2666-e2674. 2020
• The impact of delirium on withdrawal of life-sustaining treatment after intracerebral hemorrhage..  95:e2727-e2735. 2020
• Sex, race, and risk of dementia diagnosis after traumatic brain injury among older veterans..  95:e1768-e1775. 2020
• Association of genetic risk for Alzheimer disease and hearing impairment..  95:e2225-e2234. 2020
• Decline in kidney function over the course of adulthood and cognitive function in midlife..  95:e2389-e2397. 2020
• Sequence of Alzheimer disease biomarker changes in cognitively normal adults: A cross-sectional study..  95:e3104-e3116. 2020
• Apolipoprotein E.  95:e2086-e2094. 2020
• Clinician-judged hearing impairment and associations with neuropathologic burden..  95:e1640-e1649. 2020
• Familial language network vulnerability in primary progressive aphasia..  95:e847-e855. 2020
• Systolic blood pressure postural changes variability is associated with greater dementia risk..  95:e1932-e1940. 2020
• Cardiovascular risk factors and accelerated cognitive decline in midlife: The CARDIA Study..  95:e839-e846. 2020
• Associative memory and in vivo brain pathology in asymptomatic presenilin-1 E280A carriers..  95:e1312-e1321. 2020
• Blood biomarkers of traumatic brain injury and cognitive impairment in older veterans..  95:e1126-e1133. 2020
• The presubiculum links incipient amyloid and tau pathology to memory function in older persons..  94:e1916-e1928. 2020
• Randomized placebo-controlled trial of the effects of aspirin on dementia and cognitive decline..  95:e320-e331. 2020
• Anatomical evidence of an indirect pathway for word repetition..  94:e594-e606. 2020
• Differential neurocognitive network perturbation in amnestic and aphasic Alzheimer disease..  94:e699-e704. 2020
• Diet pattern and prodromal features of Parkinson disease..  95:e2095-e2108. 2020
• Disease modification and biomarker development in Parkinson disease: Revision or reconstruction?.  94:481-494. 2020
• GBA.  95:e685-e696. 2020
• LRRK2.  95:e3428-e3437. 2020
• Telemedicine in neurology: Telemedicine Work Group of the American Academy of Neurology update..  94:30-38. 2019
• APOE.  94:e607-e612. 2019
• Relation between 20-year income volatility and brain health in midlife: The CARDIA study..  93:e1890-e1899. 2019
• Navigating monoclonal antibody use in breastfeeding women: Do no harm or do little good?.  93:668-672. 2019
• Clinical EEG slowing correlates with delirium severity and predicts poor clinical outcomes..  93:e1260-e1271. 2019
• High-precision plasma β-amyloid 42/40 predicts current and future brain amyloidosis..  93:e1647-e1659. 2019
• Midlife adiposity predicts cognitive decline in the prospective Multicenter AIDS Cohort Study..  93:e261-e271. 2019
• Cross-sectional associations of tau-PET signal with cognition in cognitively unimpaired adults..  93:e29-e39. 2019
• Framing advance care planning in Parkinson disease: Patient and care partner perspectives..  92:e2571-e2579. 2019
• Dietary patterns during adulthood and cognitive performance in midlife: The CARDIA study..  92:e1589-e1599. 2019
• The prognostic value of ATN Alzheimer biomarker profiles in cognitively normal individuals..  92:643-644. 2019
• Perivascular spaces contribute to cognition beyond other small vessel disease markers..  92:e1309-e1321. 2019
• Vitamin D levels and risk of delirium: A mendelian randomization study in the UK Biobank..  92:e1387-e1394. 2019
• Genetic and lifestyle risk factors for MRI-defined brain infarcts in a population-based setting..  92:e486-503. 2019
• Physical activity and prodromal features of Parkinson disease..  93:e2157-e2169. 2019
• Prediagnostic plasma metabolomics and the risk of amyotrophic lateral sclerosis..  92:e2089-e2100. 2019
• Revisiting protein aggregation as pathogenic in sporadic Parkinson and Alzheimer diseases..  92:329-337. 2019
• Sex differences by design and outcome in the Safety of Urate Elevation in PD (SURE-PD) trial..  93:e1328-e1338. 2019
• Word comprehension in temporal cortex and Wernicke area: A PPA perspective..  92:e224-e233. 2018
• Military-related risk factors in female veterans and risk of dementia..  92:e205-e211. 2018
• CNS disease-related protein variants as blood-based biomarkers in traumatic brain injury..  91:702-709. 2018
• Longitudinal cognitive and biomarker changes in dominantly inherited Alzheimer disease..  91:e1295-e1306. 2018
• APOE.  91:e1182-e1195. 2018
• Utilizing semantic intrusions to identify amyloid positivity in mild cognitive impairment..  91:e976-e984. 2018
• Influence of tau PET, amyloid PET, and hippocampal volume on cognition in Alzheimer disease..  91:e859-e866. 2018
• Serum glutamine and hospital-acquired infections after aneurysmal subarachnoid hemorrhage..  91:e421-e426. 2018
• Baseline NAWM structural integrity and CBF predict periventricular WMH expansion over time..  90:e2119-e2126. 2018
• Mild TBI and risk of Parkinson disease: A Chronic Effects of Neurotrauma Consortium Study..  90:e1771-e1779. 2018
• APOE.  90:e1605-e1612. 2018
• Brain structure and cognition 3 years after the end of an early menopausal hormone therapy trial..  90:e1404-e1412. 2018
• Age-accelerated cognitive decline in asymptomatic adults with CSF β-amyloid..  90:e1306-e1315. 2018
• Biomarker pattern of ARIA-E participants in phase 3 randomized clinical trials with bapineuzumab..  90:e877-e886. 2018
• Neurogranin as a predictor of memory and executive function decline in MCI patients..  90:e887-e895. 2018
• Dementia and motor vehicle crash hospitalizations: Role of physician reporting laws..  90:e808-e813. 2018
• Integration of risk factors for Parkinson disease in 2 large longitudinal cohorts..  90:e1646-e1653. 2018
• Neurology residency training in 2017: A survey of preparation, perspectives, and plans..  92:76-83. 2018
• Prediagnostic plasma branched-chain amino acids and the risk of amyotrophic lateral sclerosis..  92:e2081-e2088. 2018
• Multiple pathways of reserve simultaneously present in cognitively normal older adults..  90:e197-e205. 2017
• Vascular and dopaminergic contributors to mild parkinsonian signs in older adults..  90:e223-e229. 2017
• Alzheimer's Disease-Related Dementias Summit 2016: National research priorities..  89:2381-2391. 2017
• Lower cardiac index levels relate to lower cerebral blood flow in older adults..  89:2327-2334. 2017
• COL4A2.  89:1829-1839. 2017
• Metformin vs sulfonylurea use and risk of dementia in US veterans aged ≥65 years with diabetes..  89:1877-1885. 2017
• Neurogranin, a synaptic protein, is associated with memory independent of Alzheimer biomarkers..  89:1782-1788. 2017
• Sex differences in the prevalence of genetic mutations in FTD and ALS: A meta-analysis..  89:1633-1642. 2017
• Subjective memory complaints in preclinical autosomal dominant Alzheimer disease..  89:1464-1470. 2017
• Longitudinal diffusion changes following postoperative delirium in older people without dementia..  89:1020-1027. 2017
• Developing an outline for teleneurology curriculum: AAN Telemedicine Work Group recommendations..  89:951-959. 2017
• Magnesium, hemostasis, and outcomes in patients with intracerebral hemorrhage..  89:813-819. 2017
• Slowing gait and risk for cognitive impairment: The hippocampus as a shared neural substrate..  89:336-342. 2017
• Functional network integrity presages cognitive decline in preclinical Alzheimer disease..  89:29-37. 2017
• BDNF.  88:2098-2106. 2017
• Effect of a long-term intensive lifestyle intervention on prevalence of cognitive impairment..  88:2026-2035. 2017
• A phase 3 trial of IV immunoglobulin for Alzheimer disease..  88:1768-1775. 2017
• Hippocampal hypometabolism in older adults with memory complaints and increased amyloid burden..  88:1759-1767. 2017
• Cued memory decline in biomarker-defined preclinical Alzheimer disease..  88:1431-1438. 2017
• Physical activity and hippocampal volume in middle-aged patients with type 1 diabetes..  88:1564-1570. 2017
• Multimodal characterization of older APOE2 carriers reveals selective reduction of amyloid load..  88:569-576. 2017
• Intake of dairy foods and risk of Parkinson disease..  89:46-52. 2017
• Olfaction and risk of dementia in a biracial cohort of older adults..  88:456-462. 2016
• The link between sleep-disordered breathing and cognition in the elderly: New opportunities?.  88:424-425. 2016
• Dementia risk in renal dysfunction: A systematic review and meta-analysis of prospective studies..  88:198-208. 2016
• Asymptomatic Alzheimer disease: Defining resilience..  87:2443-2450. 2016
• Hippocampal volumes predict risk of dementia with Lewy bodies in mild cognitive impairment..  87:2317-2323. 2016
• Slow gait, white matter characteristics, and prior 10-year interleukin-6 levels in older adults..  87:1993-1999. 2016
• Aphasic variant of Alzheimer disease: Clinical, anatomic, and genetic features..  87:1337-43. 2016
• Effects of hormone therapy on brain structure: A randomized controlled trial..  87:887-96. 2016
• Temporal T807 binding correlates with CSF tau and phospho-tau in normal elderly..  87:920-6. 2016
• Neuroimaging overuse is more common in Medicare compared with the VA..  87:792-8. 2016
• Polygenic risk of Alzheimer disease is associated with early- and late-life processes..  87:481-8. 2016
• A/T/N: An unbiased descriptive classification scheme for Alzheimer disease biomarkers..  87:539-47. 2016
• Accelerating rates of cognitive decline and imaging markers associated with β-amyloid pathology..  86:1887-96. 2016
• Frontotemporal networks and behavioral symptoms in primary progressive aphasia..  86:1393-1399. 2016
• Hostile attitudes and effortful coping in young adulthood predict cognition 25 years later..  86:1227-34. 2016
• Chronic kidney disease, cerebral blood flow, and white matter volume in hypertensive adults..  86:1208-16. 2016
• Prospective study of plasma urate and risk of Parkinson disease in men and women..  86:520-6. 2016
• Memory complaints and risk of cognitive impairment after nearly 2 decades among older women..  85:1852-8. 2015
• Mediterranean diet and brain structure in a multiethnic elderly cohort..  85:1744-51. 2015
• Evaluation of outcome measures for neurogenic claudication: A patient-centered approach..  85:1250-6. 2015
• Cerebral amyloidosis associated with cognitive decline in autosomal dominant Alzheimer disease..  85:790-8. 2015
• Amyloid-β 11C-PiB-PET imaging results from 2 randomized bapineuzumab phase 3 AD trials..  85:692-700. 2015
• Postmenopausal hormone therapy, type 2 diabetes mellitus, and brain volumes..  85:1131-8. 2015
• Cognitive correlates of white matter lesion load and brain atrophy: the Northern Manhattan Study..  85:441-9. 2015
• Cognitive activity relates to cognitive performance but not to Alzheimer disease biomarkers..  85:48-55. 2015
• Subjective cognitive concerns, amyloid-β, and neurodegeneration in clinically normal elderly..  85:56-62. 2015
• Longitudinal patient-oriented outcomes in neuropathy: Importance of early detection and falls..  85:71-9. 2015
• Subclinical cerebrovascular disease inversely associates with learning ability: The NOMAS..  84:2362-7. 2015
• Tetrahydrocannabinol for neuropsychiatric symptoms in dementia: A randomized controlled trial..  84:2338-46. 2015
• Odor identification and Alzheimer disease biomarkers in clinically normal elderly..  84:2153-60. 2015
• Association of hospitalization with long-term cognitive and brain MRI changes in the ARIC cohort..  84:1443-53. 2015
• "Noncognitive" symptoms of early Alzheimer disease: a longitudinal analysis..  84:617-22. 2015
• PARK10 is a major locus for sporadic neuropathologically confirmed Parkinson disease..  84:972-80. 2015
• Brain amyloidosis ascertainment from cognitive, imaging, and peripheral blood protein measures..  84:729-37. 2015
• Development and validation of risk index for cognitive decline using blood-derived markers..  84:696-702. 2015
• Inflammation, negative nitrogen balance, and outcome after aneurysmal subarachnoid hemorrhage..  84:680-7. 2015
• Olfactory deficits predict cognitive decline and Alzheimer dementia in an urban community..  84:182-9. 2014
• Factors associated with cognitive evaluations in the United States..  84:64-71. 2014
• Physical activity attenuates age-related biomarker alterations in preclinical AD..  83:1753-60. 2014
• Cervical spine fracture associated with ankylosing spondylitis..  83:-. 2014
• Asymmetry of cortical decline in subtypes of primary progressive aphasia..  83:1184-91. 2014
• Vitamin D and the risk of dementia and Alzheimer disease..  83:920-8. 2014
• Traumatic brain injury and risk of dementia in older veterans..  83:312-9. 2014
• Symptom onset in autosomal dominant Alzheimer disease: a systematic review and meta-analysis..  83:253-60. 2014
• Amyloid and APOE ε4 interact to influence short-term decline in preclinical Alzheimer disease..  82:1760-7. 2014
• Cardiorespiratory fitness and cognitive function in middle age: the CARDIA study..  82:1339-46. 2014
• Contribution of Alzheimer disease to mortality in the United States..  82:1045-50. 2014
• Long-term survival after ischemic stroke in patients with atrial fibrillation..  82:1033-7. 2014
• Acute infection contributes to racial disparities in stroke mortality..  82:914-21. 2014
• Higher RBC EPA + DHA corresponds with larger total brain and hippocampal volumes: WHIMS-MRI study..  82:435-42. 2014
• Rates of β-amyloid accumulation are independent of hippocampal neurodegeneration..  82:1605-12. 2014
• Supply and demand analysis of the current and future US neurology workforce..  82:2254-5. 2014
• Long-term predictive value of the Framingham Risk Score for Stroke in HIV-positive vs HIV-negative men..  81:2094-102. 2013
• ω-3 fatty acids and domain-specific cognitive aging: secondary analyses of data from WHISCA..  81:1484-91. 2013
• The pattern of atrophy in familial Alzheimer disease: volumetric MRI results from the DIAN study..  81:1425-33. 2013
• Naming vs knowing faces in primary progressive aphasia: a tale of 2 hemispheres..  81:658-64. 2013
• Neuropathologic basis of white matter hyperintensity accumulation with advanced age..  81:977-83. 2013
• Cocoa, neurovascular coupling, and neurodegeneration: the good, the bad, and the ugly..  81:863-4. 2013
• Imaging markers for Alzheimer disease: which vs how..  81:487-500. 2013
• Impaired default network functional connectivity in autosomal dominant Alzheimer disease..  81:736-44. 2013
• Clinical Reasoning: a 44-year-old woman with headache followed by sudden neurologic decline..  80:e136-41. 2013
• Cognitive reserve associated with FDG-PET in preclinical Alzheimer disease..  80:1194-201. 2013
• Amyloid imaging and CSF biomarkers in predicting cognitive impairment up to 7.5 years later..  80:1784-91. 2013
• CSF biomarkers of Alzheimer disease: "noncognitive" outcomes..  81:2028-31. 2013
• Unrecognized vitamin D3 deficiency is common in Parkinson disease: Harvard Biomarker Study..  81:1531-7. 2013
• Visualization of nigrosome 1 and its loss in PD: pathoanatomical correlation and in vivo 7 T MRI..  81:534-40. 2013
• Teaching Video NeuroImages: phenytoin-induced orofacial dyskinesias..  79:-. 2012
• Stroke symptoms signal worse outcomes in patients with end-stage renal disease..  79:960-1. 2012
• Trajectory of white matter hyperintensity burden preceding mild cognitive impairment..  79:741-7. 2012
• Amyloid-β assessed by florbetapir F 18 PET and 18-month cognitive decline: a multicenter study..  79:1636-44. 2012
• Novel late-onset Alzheimer disease loci variants associate with brain gene expression..  79:221-8. 2012
• Genotype patterns at PICALM, CR1, BIN1, CLU, and APOE genes are associated with episodic memory..  78:1464-71. 2012
• Pearls & Oysters: the effects of renal replacement therapy on cerebral autoregulation..  78:e36-8. 2012
• Memory after silent stroke: hippocampus and infarcts both matter..  78:38-46. 2012
• CSF VILIP-1 predicts rates of cognitive decline in early Alzheimer disease..  78:709-19. 2012
• Caffeine in Parkinson disease: better for cruise control than snooze patrol?.  79:616-8. 2012
• Habitual intake of dietary flavonoids and risk of Parkinson disease..  78:1138-45. 2012
• Indicators of amyloid burden in a population-based study of cognitively normal elderly..  79:1570-7. 2012
• Plasma multianalyte profiling in mild cognitive impairment and Alzheimer disease..  79:897-905. 2012
• Nutrient biomarker patterns, cognitive function, and MRI measures of brain aging..  78:241-9. 2011
• Effect of rebleeding on the course and incidence of vasospasm after subarachnoid hemorrhage..  78:31-7. 2011
• Amyloid vs FDG-PET in the differential diagnosis of AD and FTLD..  77:2034-42. 2011
• A phase 2 randomized trial of ELND005, scyllo-inositol, in mild to moderate Alzheimer disease..  77:1253-62. 2011
• Advanced glycation end product level, diabetes, and accelerated cognitive aging..  77:1351-6. 2011
• Plasma Aβ and PET PiB binding are inversely related in mild cognitive impairment..  77:125-31. 2011
• Progression of language decline and cortical atrophy in subtypes of primary progressive aphasia..  76:1804-10. 2011
• Distinct clinical and metabolic deficits in PCA and AD are not related to amyloid distribution..  76:1789-96. 2011
• Alzheimer-signature MRI biomarker predicts AD dementia in cognitively normal adults..  76:1395-402. 2011
• Defaulting on the default network: increased risk for dementia..  76:498-500. 2011
• Improving CSF biomarker accuracy in predicting prevalent and incident Alzheimer disease..  76:501-10. 2011
• Use of ibuprofen and risk of Parkinson disease..  76:863-9. 2011
• HIV-associated neurocognitive disorders persist in the era of potent antiretroviral therapy: CHARTER Study..  75:2087-96. 2010
• Albuminuria and the risk of incident stroke and stroke types in older adults..  75:1343-50. 2010
• Use of anticholinergics and the risk of cognitive impairment in an African American population..  75:152-9. 2010
• Longitudinal fMRI in elderly reveals loss of hippocampal activation with clinical decline..  74:1969-76. 2010
• Cognitively unimpaired HIV-positive subjects do not have increased 11C-PiB: a case-control study..  75:111-5. 2010
• The delayed-start study in Parkinson disease: can't satisfy everyone: Rasagiline, Parkinson neuroprotection, and delayed-start trials: still no satisfaction?.  75:1943-4; author reply 1944-5. 2010
• A phase 2 multiple ascending dose trial of bapineuzumab in mild to moderate Alzheimer disease..  73:2061-70. 2009
• ALS motor phenotype heterogeneity, focality, and spread: deconstructing motor neuron degeneration..  73:805-11. 2009
• Conflict monitoring in early frontotemporal dementia..  73:349-55. 2009
• Cognitive impairment risk: white matter hyperintensity progression matters..  73:120-5. 2009
• Surrogate consent for dementia research: a national survey of older Americans..  72:149-55. 2009
• CSF biomarkers of Alzheimer disease in HIV-associated neurologic disease..  73:1982-7. 2009
• Delirium accelerates cognitive decline in Alzheimer disease..  72:1570-5. 2009
• Family history of melanoma and Parkinson disease risk..  73:1286-91. 2009
• Obesity and restless legs syndrome in men and women..  72:1255-61. 2009
• Survival in Alzheimer disease: a multiethnic, population-based study of incident cases..  71:1489-95. 2008
• A novel PRNP-P105S mutation associated with atypical prion disease and a rare PrPSc conformation..  71:1431-8. 2008
• Fatigue in levodopa-naive subjects with Parkinson disease..  71:481-5. 2008
• Use of statins and incidence of dementia and cognitive impairment without dementia in a cohort study..  71:344-50. 2008
• APOE epsilon 4 allele predicts faster cognitive decline in mild Alzheimer disease..  70:1842-9. 2008
• A longitudinal study of drivers with Alzheimer disease..  70:1171-8. 2008
• No advantage of A beta 42-lowering NSAIDs for prevention of Alzheimer dementia in six pooled cohort studies..  70:2291-8. 2008
• Trajectories of brain loss in aging and the development of cognitive impairment..  70:828-33. 2007
• Vascular factors predict rate of progression in Alzheimer disease..  69:1850-8. 2007
• Relationship of fMRI activation to clinical trial memory measures in Alzheimer disease..  69:1331-41. 2007
• Mediterranean diet and Alzheimer disease mortality..  69:1084-93. 2007
• Does statin use decrease the amount of Alzheimer disease pathology in the brain?.  69:E8-11. 2007
• Brain volumes in Guam dementia vs Parkinson dementia complex vs aging Chamorro adults..  69:196-9. 2007
• Impairment of nonverbal recognition in Alzheimer disease: a PET O-15 study..  69:32-41. 2007
• Inflammatory markers and the risk of Alzheimer disease: the Framingham Study..  68:1902-8. 2007
• Cycad exposure and risk of dementia, MCI, and PDC in the Chamorro population of Guam..  68:1764-71. 2007
• Prevalence of dementia in Chamorros on Guam: relationship to age, gender, education, and APOE..  68:1772-81. 2007
• Predictors of diagnosis in Huntington disease..  68:1710-7. 2007
• AMPA potentiator treatment of cognitive deficits in Alzheimer disease..  68:1008-12. 2007
• Hippocampal and entorhinal atrophy in mild cognitive impairment: prediction of Alzheimer disease..  68:828-36. 2007
• Fluctuations of CSF amyloid-beta levels: implications for a diagnostic and therapeutic biomarker..  68:666-9. 2007
• Hypertension, hypercholesterolemia, diabetes, and risk of Parkinson disease..  69:1688-95. 2007
• Temporal relationship between cigarette smoking and risk of Parkinson disease..  68:764-8. 2007
• Multiple system atrophy presenting with language impairment..  67:726-7. 2006
• Longitudinal study of effects of patient characteristics on direct costs in Alzheimer disease..  67:998-1005. 2006
• Pilot clinical trial of gabapentin to decrease postoperative delirium in older patients..  67:1251-3. 2006
• Projected costs of ischemic stroke in the United States..  67:1390-5. 2006
• Rapid infusion of cold saline (4 degrees C) as adjunctive treatment of fever in patients with brain injury..  66:1739-41. 2006
• Clinical features associated with costs in early AD: baseline data from the Predictors Study..  66:1021-8. 2006
• Brain volume loss in MCI predicts dementia..  66:233-5. 2006
• Inclusion-body myositis and Alzheimer disease: two sides of the same coin, or different currencies altogether?.  66:S65-8. 2006
• Effects of a gamma-secretase inhibitor in a randomized study of patients with Alzheimer disease..  66:602-4. 2006
• fMRI evidence of compensatory mechanisms in older adults at genetic risk for Alzheimer disease..  65:1514-5; author reply 1514-5. 2005
• Increased hippocampal activation in mild cognitive impairment compared to normal aging and AD..  65:404-11. 2005
• Ethnic differences in acetylcholinesterase inhibitor use for Alzheimer disease..  65:159-62. 2005
• Cognitive function predicts first-time stroke and heart disease..  64:1750-5. 2005
• Motor signs predict poor outcomes in Alzheimer disease..  64:1696-703. 2005
• Neuropsychological predictors of dependency in patients with Alzheimer disease..  64:1027-31. 2005
• Immunization therapy for Alzheimer disease?.  64:10-2. 2005
• Physical activity and the risk of Parkinson disease..  64:664-9. 2005
• Evaluation of HIV RNA and markers of immune activation as predictors of HIV-associated dementia..  63:2084-90. 2004
• Impact of antioxidants, zinc, and copper on cognition in the elderly: a randomized, controlled trial..  63:1705-7. 2004
• Motor signs during the course of Alzheimer disease..  63:975-82. 2004
• APOE-dependent PET patterns of brain activation in Alzheimer disease..  63:913-5. 2004
• Beta-synuclein gene alterations in dementia with Lewy bodies..  63:805-11. 2004
• Psychiatric comorbidities in patients with Parkinson disease and psychosis..  63:293-300. 2004
• Clinical profile and course of cognitively normal patients evaluated in memory disorders clinics..  62:1639-42. 2004
• Genetic influences on memory performance in familial Alzheimer disease..  62:414-21. 2004
• Plasma A[beta]40 and A[beta]42 and Alzheimer's disease: relation to age, mortality, and risk..  61:1185-90. 2003
• Wrinkles and folds of the prion protein..  61:1168-9. 2003
• Changes in premorbid brain volume predict Alzheimer's disease pathology..  61:487-92. 2003
• Semantic memory deficit with a left thalamic infarct..  61:252-4. 2003
• Cognition following bilateral implants of embryonic dopamine neurons in PD: a double blind study..  60:1938-43. 2003
• Inter-rater reliability of a clinical staging of HIV-associated cognitive impairment..  60:1467-73. 2003
• Natural history of cognitive decline in the old old..  60:1489-94. 2003
• Neuroprotective agents for clinical trials in Parkinson's disease: a systematic assessment..  60:1234-40. 2003
• Predictors of nursing home placement in Huntington disease..  60:998-1001. 2003
• Spinal meningioma causing diffuse leptomeningeal enhancement..  60:350-1. 2003
• Adenosine A2A receptors in neuroadaptation to repeated dopaminergic stimulation: implications for the treatment of dyskinesias in Parkinson's disease..  61:S74-81. 2003
• Caffeine, postmenopausal estrogen, and risk of Parkinson's disease..  60:790-5. 2003
• Monoamine oxidase B inhibition and neuroprotection: studies on selective adenosine A2A receptor antagonists..  61:S62-8. 2003
• Neuroprotection by caffeine and more specific A2A receptor antagonists in animal models of Parkinson's disease..  61:S55-61. 2003
• Sleep regulation in adenosine A2A receptor-deficient mice..  61:S94-6. 2003
• The association of incident dementia with mortality in PD..  59:1708-13. 2002
• Premorbid weight, body mass, and varsity athletics in ALS..  59:773-5. 2002
• "Out, damned spot! out, I say!...": issues related to prion decontamination..  59:488-9. 2002
• Mortality in patients with dementia after ischemic stroke..  59:537-43. 2002
• Primary care expenditures before the onset of Alzheimer's disease..  59:573-8. 2002
• A national study of the quantity and cost of informal caregiving for the elderly with stroke..  58:1754-9. 2002
• Phases of A beta-deposition in the human brain and its relevance for the development of AD..  58:1791-800. 2002
• Association between the APOE genotype and psychopathologic symptoms in Alzheimer's disease..  58:1182-8. 2002
• The relationship of hypertension in the elderly to AD, vascular dementia, and cognitive function..  58:1175-81. 2002
• Functional deficits in patients with mild cognitive impairment: prediction of AD..  58:758-64. 2002
• Reduced intraepidermal nerve fiber density in HIV-associated sensory neuropathy..  58:115-9. 2002
• Caffeinated clues and the promise of adenosine A(2A) antagonists in PD..  58:1154-60. 2002
• Influence of leisure activity on the incidence of Alzheimer's disease..  57:2236-42. 2001
• Inherited prion disease caused by the V210I mutation: transmission to transgenic mice..  57:2198-205. 2001
• Clinical trials in HIV-associated cognitive impairment: cognitive and functional outcomes..  56:415-8. 2001
• Incidence of AD in African-Americans, Caribbean Hispanics, and Caucasians in northern Manhattan..  56:49-56. 2001
• Presenilin-1-associated abnormalities in regional cerebral perfusion..  56:1545-51. 2001
• Different brain networks mediate task performance in normal aging and AD: defining compensation..  55:1291-7. 2000
• Late-onset SCA2: 33 CAG repeats are sufficient to cause disease..  55:569-72. 2000
• Motor impairment in PD: relationship to incident dementia and age..  55:539-44. 2000
• Poor verbal working memory across intellectual level in boys with Duchenne dystrophy..  54:2127-32. 2000
• Frequency and clinical determinants of dementia after ischemic stroke..  54:1124-31. 2000
• Rate of memory decline in AD is related to education and occupation: cognitive reserve?.  53:1942-7. 1999
• Influence of APOE genotype on familial aggregation of AD in an urban population..  53:789-94. 1999
• Assessment of cognition in advanced AD: the test for severe impairment..  52:1689-91. 1999
• Selective decline in memory function among healthy elderly..  52:1392-6. 1999
• The influence of smoking on the risk of Alzheimer's disease..  52:1408-12. 1999
• Risk of Alzheimer's disease in relatives of Parkinson's disease patients with and without dementia..  52:719-24. 1999
• Increased risk of mortality in AD patients with higher education?.  51:-. 1998
• Creutzfeldt-Jakob disease (CJD) after blood product transfusion from a donor with CJD..  50:1872-3. 1998
• Cognitive test performance among nondemented elderly African Americans and whites..  50:1238-45. 1998
• Postmenopausal estrogen use and Parkinson's disease with and without dementia..  50:1141-3. 1998
• Cognitive function in nondemented older women who took estrogen after menopause..  50:368-73. 1998
• Changes of hippocampal N-acetyl aspartate and volume in Alzheimer's disease. A proton MR spectroscopic imaging and MRI study..  49:1513-21. 1997
• An association between head circumference and Alzheimer's disease in a population-based study of aging and dementia..  49:30-7. 1997
• Participation in clinical trials and long-term outcomes in Alzheimer's disease..  49:38-43. 1997
• Dementia after stroke increases the risk of long-term stroke recurrence..  48:1317-25. 1997
• Mutation of the prion protein gene at codon 208 in familial Creutzfeldt-Jakob disease..  47:1305-12. 1996
• A preliminary study of apolipoprotein E genotype and psychiatric manifestations of Alzheimer's disease..  47:256-9. 1996
• Neurologic consequences of HTLV-II infection in injection-drug users..  46:1556-60. 1996
• The Clinical Dementia Rating scale: community-based validation of "profound' and "terminal' stages..  46:1746-9. 1996
• Noninvasive perfusion MRI in Alzheimer's disease: a preliminary report..  47:1339-42. 1996
• Prion disease (PrP-A117V) presenting with ataxia instead of dementia..  45:2042-50. 1995
• Consistency of clinical diagnosis in a community-based longitudinal study of dementia and Alzheimer's disease..  45:2159-64. 1995
• Neuropsychological changes in a prospectively followed cohort of homosexual and bisexual men with and without HIV infection..  45:467-72. 1995
• Neuropsychological characteristics of preclinical dementia in Parkinson's disease..  45:1691-6. 1995
• Neuropsychological detection and characterization of preclinical Alzheimer's disease..  45:957-62. 1995
• Neuropsychological test performance in African-American and white patients with Alzheimer's disease..  45:2207-11. 1995
• Plasmapheresis in fulminant acute disseminated encephalomyelitis..  45:824-7. 1995
• Subtle extrapyramidal signs and incident dementia: a follow-up analysis..  45:-. 1995
• Kennedy's disease..  43:2424-5. 1993
• Word comprehension in temporal cortex and Wernicke area: A PPA perspective 2019
• Rapid Revascularization of Simultaneous Bilateral ICA Occlusions causing Coma 2018
• Word comprehension in temporal cortex and Wernicke area 2018
• Comparative analysis of C9orf72 and sporadic disease in an ALS clinic population 2016
• Comparative analysis of C9orf72 and sporadic disease in an ALS clinic population. 2016
• Rapid Revascularization of Simultaneous Bilateral ICA Occlusions causing Coma 2018

Identity

International Standard Serial Number (ISSN)

• 0028-3878
• 1526-632X
• 1526632X 00283878